从甜菊糖开发抗糖尿病纳米药物。
Development of antidiabetic nanomedicine from stevioside.
机构信息
Biotechnology Division, Institute of Himalayan Bioresource Technology (Council of Scientific and Industrial Research, India), Palampur 176061, India.
出版信息
J Biomed Nanotechnol. 2011 Feb;7(1):54-5. doi: 10.1166/jbn.2011.1198.
PMID:21485800
Abstract
Stevioside, a non-caloric sweetener has huge therapeutic potential as an antidiabetic biomolecule. Stevioside nano-bioconjugated on PEG-PLA nanoparticles of size 150-170 nm showed the initial burst phase followed by the slow controlled release of 2 h and 21 days respectively.
摘要
甜菊苷是一种无热量的甜味剂，具有巨大的治疗潜力，可作为一种抗糖尿病生物分子。粒径为 150-170nm 的 PEG-PLA 纳米粒上接枝的甜菊苷显示出初始突释相，随后分别缓慢控制释放 2 小时和 21 天。
Zotero 插件